STOCK TITAN

Nalu Medical Appoints Veteran Medtech Executive Raymond W. Cohen Chairman of its Board of Directors

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
management

Nalu Medical has appointed Raymond W. Cohen as chairman of its board of directors. Cohen previously served as CEO and board member of Axonics, a medical device company he co-founded in 2013 and took public in 2018. Under his leadership, Axonics achieved recognition as the fastest-growing company in the Americas by Deloitte and Financial Times in 2021 and 2022.

Cohen recently oversaw Axonics' $3.7 billion sale to Boston Scientific (NYSE: BSX) in November 2024. He also served as chairman of SoniVie, which was sold to BSX for $600 million in March 2025. Currently, he serves on the board of Kestra Medical Technologies (Nasdaq: KMTS), which recently completed a $232 million IPO.

Nalu Medical ha nominato Raymond W. Cohen come presidente del suo consiglio di amministrazione. Cohen ha precedentemente ricoperto il ruolo di CEO e membro del consiglio di Axonics, un'azienda di dispositivi medici che ha co-fondato nel 2013 e quotato in borsa nel 2018. Sotto la sua guida, Axonics ha ottenuto il riconoscimento come la società in più rapida crescita nelle Americhe da parte di Deloitte e Financial Times nel 2021 e 2022.

Cohen ha recentemente supervisionato la vendita di Axonics per 3,7 miliardi di dollari a Boston Scientific (NYSE: BSX) nel novembre 2024. Ha anche ricoperto il ruolo di presidente di SoniVie, che è stata venduta a BSX per 600 milioni di dollari nel marzo 2025. Attualmente, fa parte del consiglio di Kestra Medical Technologies (Nasdaq: KMTS), che ha recentemente completato un'IPO da 232 milioni di dollari.

Nalu Medical ha nombrado a Raymond W. Cohen como presidente de su junta directiva. Cohen anteriormente fue CEO y miembro de la junta de Axonics, una empresa de dispositivos médicos que cofundó en 2013 y salió a bolsa en 2018. Bajo su liderazgo, Axonics fue reconocida como la empresa de más rápido crecimiento en las Américas por Deloitte y Financial Times en 2021 y 2022.

Cohen recientemente supervisó la venta de Axonics por 3.7 mil millones de dólares a Boston Scientific (NYSE: BSX) en noviembre de 2024. También fue presidente de SoniVie, que fue vendida a BSX por 600 millones de dólares en marzo de 2025. Actualmente, forma parte de la junta de Kestra Medical Technologies (Nasdaq: KMTS), que recientemente completó una OPI de 232 millones de dólares.

Nalu MedicalRaymond W. Cohen을 이사회의 의장으로 임명했습니다. Cohen은 2013년에 공동 설립하고 2018년에 상장한 의료기기 회사 Axonics의 CEO 및 이사로 재직했습니다. 그의 리더십 아래, Axonics는 2021년과 2022년에 Deloitte와 Financial Times로부터 아메리카에서 가장 빠르게 성장하는 회사로 인정받았습니다.

Cohen은 최근 Axonics의 37억 달러 판매를 Boston Scientific (NYSE: BSX)에게 2024년 11월에 감독했습니다. 그는 또한 2025년 3월에 BSX에 6억 달러에 판매된 SoniVie의 의장으로 재직했습니다. 현재 그는 최근 2억 3200만 달러 규모의 IPO를 완료한 Kestra Medical Technologies (Nasdaq: KMTS)의 이사로 활동하고 있습니다.

Nalu Medical a nommé Raymond W. Cohen président de son conseil d'administration. Cohen a précédemment été PDG et membre du conseil d'administration de Axonics, une entreprise de dispositifs médicaux qu'il a cofondée en 2013 et introduite en bourse en 2018. Sous sa direction, Axonics a été reconnue comme l'entreprise à la croissance la plus rapide des Amériques par Deloitte et le Financial Times en 2021 et 2022.

Cohen a récemment supervisé la vente d'Axonics pour 3,7 milliards de dollars à Boston Scientific (NYSE: BSX) en novembre 2024. Il a également été président de SoniVie, qui a été vendue à BSX pour 600 millions de dollars en mars 2025. Actuellement, il siège au conseil de Kestra Medical Technologies (Nasdaq: KMTS), qui a récemment complété une introduction en bourse de 232 millions de dollars.

Nalu Medical hat Raymond W. Cohen zum Vorsitzenden seines Vorstands ernannt. Cohen war zuvor CEO und Vorstandsmitglied von Axonics, einem Medizintechnikunternehmen, das er 2013 mitbegründete und 2018 an die Börse brachte. Unter seiner Führung wurde Axonics 2021 und 2022 von Deloitte und Financial Times als das am schnellsten wachsende Unternehmen in den Amerikas anerkannt.

Cohen überwachte kürzlich den Verkauf von Axonics für 3,7 Milliarden Dollar an Boston Scientific (NYSE: BSX) im November 2024. Er war auch Vorsitzender von SoniVie, das im März 2025 für 600 Millionen Dollar an BSX verkauft wurde. Derzeit ist er Mitglied des Vorstands von Kestra Medical Technologies (Nasdaq: KMTS), das kürzlich einen Börsengang über 232 Millionen Dollar abgeschlossen hat.

Positive
  • Appointment of highly successful MedTech executive with proven track record of company sales to BSX
  • New chairman has experience in taking companies public and driving significant growth
  • Chairman's expertise specifically in neuromodulation aligns with company's product focus
Negative
  • None.

CARLSBAD, Calif.--(BUSINESS WIRE)-- Nalu Medical, Inc. (“Nalu”) announced today the appointment of Raymond W. Cohen to serve as chairman of its board of directors.

Raymond Cohen served as the chief executive officer and member of the board of directors of Nasdaq-listed Axonics, Inc., a medical device company he co-founded in 2013 and took public in late October 2018. Axonics ranked No. 1 on the Deloitte Technology Fast 500™ and the Financial Times ranking of the fastest growing companies in the Americas in 2021 and 2022. Cohen retired from Axonics following the November 2024 close of its $3.7 billion sale to Boston Scientific Corporation (NYSE: BSX).

Following the sale of Axonics, Cohen was named chairman of the board of SoniVie, Ltd., a privately held, Israel-based developer of a renal denervation system to treat hypertension. Cohen was instrumental in the March 2025 announced sale to BSX for $600 million. In addition, Cohen serves on the board of directors of Kestra Medical Technologies (Nasdaq: KMTS), a commercial stage company manufacturing and marketing a wearable defibrillator product for patients at temporary risk of cardiac arrest. Kestra completed an oversubscribed IPO in early March, raising $232 million in gross proceeds.

Tom West, Nalu CEO and president, said, "We look forward to benefiting from Mr. Cohen’s broad experience in growing MedTech companies and his expertise in neuromodulation as we seek to significantly increase adoption of our peripheral nerve stimulation system.”

About Raymond W. Cohen

Raymond Cohen is an accredited public company director with more than 40 years of experience in the life sciences industry. He received the 2024 MedTech MVP Award and was also named Businessperson of the Year in 2024 by the Orange County Business Journal. In 2021, Cohen received a lifetime achievement award from SoCalBio for his four decades of work in medical technology. In late 2020, Cohen was named Entrepreneur of the Year by Ernst & Young for the Pacific Southwest United States.

About Nalu Medical

Nalu is a Carlsbad, California-based medical technology company focused on developing and commercializing innovative and minimally invasive solutions for patients with chronic neuropathic pain. The Nalu Neurostimulation System delivers gentle electrical pulses to the nervous system to modulate pain signals before they get to the brain. The Nalu System was designed to address major unmet needs in the treatment of chronic neuropathic pain and provide a differentiated value proposition for patients and physicians.

About the Nalu Neurostimulation System

The Nalu System consists of a fully featured, miniaturized implantable pulse generator (IPG) that is powered wirelessly by an externally worn Therapy Disc and controlled through a smartphone-based remote-control app. Despite its small size, the Nalu micro-IPG™ delivers treatment capabilities similar to larger IPGs as well as unique advantages associated with advanced waveforms, extensive programming options, exceptional upgradability, and an expected service life of 18 years. The Nalu System has been repeatedly recognized for its revolutionary technology, including being named as one of the world’s top 100 new products by R&D Magazine in 2021 and ranking number 19 in the 2023 Deloitte Technology Fast 500. It is FDA-cleared for Peripheral Nerve Stimulation (PNS) and Spinal Cord Stimulation (SCS) indications. To learn more, visit www.nalumed.com

Indications for Use

Spinal Cord Stimulation — The Nalu SCS System is indicated as the sole mitigating agent or as an adjunct to other modes of therapy used in a multidisciplinary approach for chronic intractable pain of the trunk and/or limbs, including unilateral or bilateral pain. The trial devices are solely used for trial stimulation (≤ 30 days) to determine efficacy before recommendation for a permanent (long-term) device.

Peripheral Nerve Stimulation — The Nalu PNS System is indicated for pain management in adults who have severe chronic intractable pain of peripheral nerve origin as the sole mitigating agent or as an adjunct to other modes of therapy used in a multidisciplinary approach. The Nalu Neurostimulation System for PNS is not intended to treat pain in the craniofacial region. The trial devices are solely used for trial stimulation (≤ 30 days) to determine efficacy before recommendation for a permanent (long-term) device.

Nalu, the Nalu logo, and micro-IPG are trademarks of Nalu Medical, Inc.

Media Contact

Tom West, CEO

twest@nalumed.com

Source: Nalu Medical, Inc.

FAQ

What is Raymond Cohen's track record with medical device companies before joining Nalu Medical?

Cohen co-founded Axonics in 2013, led it to become the fastest-growing company in Americas (2021-2022), and oversaw its $3.7B sale to BSX in 2024. He also led SoniVie's $600M sale to BSX in 2025.

How much was Axonics sold to Boston Scientific (BSX) for in 2024?

Axonics was sold to Boston Scientific (BSX) for $3.7 billion in November 2024.

What are Raymond Cohen's current board positions in 2025?

Cohen serves as chairman of Nalu Medical's board and is on the board of Kestra Medical Technologies (KMTS), which recently completed a $232M IPO.

What was the value of SoniVie's acquisition by Boston Scientific (BSX)?

SoniVie was acquired by Boston Scientific (BSX) for $600 million in March 2025.
Boston Scien Cp

NYSE:BSX

BSX Rankings

BSX Latest News

BSX Stock Data

138.89B
1.47B
0.2%
93.36%
0.87%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States
MARLBOROUGH